{
    "2019-11-14": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Livongo Bounces Back After Revenue Guidance Boost",
                "features": {
                    "keywords": [
                        "Livongo",
                        "Revenue",
                        "Guidance",
                        "Boost"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Microsoft",
                        "Novartis",
                        "Novo Nordisk",
                        "Tesla",
                        "General Dynamics"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "pharmaceuticals",
                        "automotive",
                        "defense"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes",
                "features": {
                    "keywords": [
                        "FDA",
                        "Panel",
                        "Votes",
                        "Against",
                        "Lilly",
                        "Jardiance",
                        "Type I Diabetes"
                    ],
                    "sentiment_score": -0.65,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}